Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Capital Expenditures (2019 - 2025)

Beam Therapeutics (BEAM) has disclosed Capital Expenditures for 7 consecutive years, with -$9.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Capital Expenditures fell 93.33% to -$9.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.3 million, a 52.4% increase, with the full-year FY2025 number at $1.3 million, up 52.4% from a year prior.
  • Capital Expenditures was -$9.9 million for Q4 2025 at Beam Therapeutics, down from $5.0 million in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $31.8 million in Q3 2022 to a low of -$9.9 million in Q4 2025.
  • A 5-year average of $6.6 million and a median of $4.1 million in 2025 define the central range for Capital Expenditures.
  • Peak YoY movement for Capital Expenditures: skyrocketed 1012.21% in 2021, then plummeted 400.52% in 2024.
  • Beam Therapeutics' Capital Expenditures stood at $13.4 million in 2021, then tumbled by 38.21% to $8.3 million in 2022, then skyrocketed by 281.79% to $31.5 million in 2023, then tumbled by 116.3% to -$5.1 million in 2024, then plummeted by 93.33% to -$9.9 million in 2025.
  • Per Business Quant, the three most recent readings for BEAM's Capital Expenditures are -$9.9 million (Q4 2025), $5.0 million (Q3 2025), and $3.1 million (Q2 2025).